Key result
Class IIIA antiarrhythmic agents should ideally lengthen refractoriness upon acceleration of the heart to exceed the cycle length of tachycardia.
This paper proposes theoretical mechanisms for developing ideal Class III antiarrhythmic agents that increase refractoriness during tachycardia rather than bradycardia.
Answers are grounded in this paper and cite their sources.
May guide rate-dependent Class III agent design; leaves open clinical efficacy in tachyarrhythmias.
Currently available antiarrhythmic agents that act by lengthening the action potential duration and refractory period exert most of their effect during bradycardia (class IIIB). Unfortunately, when these agents are most needed, i.e., during tachycardia, they lose most of their effect. In my opinion, ideally, antiarrhythmic agents need not change the electrophysiology of the normal sinus beat, but should lengthen refractoriness upon acceleration (class IIIA) of the heart until the refractory period exceeds the cycle length of the tachycardia. Three examples of how such class IIIA effects can be achieved are: (i) an upstroke-dependent activator of inward currents could form a universal class IIIA agent, (ii) a use-dependent blocker of iTO could be a great class IIIA agent in the atria, and (iii) a frequency-dependent blocker of late repolarizing currents (e.g., iKs) could be a good target for a ventricular agent.
No takes yet. Share an insight, caveat, or question.
Luc M. Hondeghem (1992) conducted an editorial in Arrhythmia. Class IIIA antiarrhythmic agents was evaluated. Class IIIA antiarrhythmic agents should ideally lengthen refractoriness upon acceleration of the heart to exceed the cycle length of tachycardia.
Synapse has enriched 10 related papers. Consider them for comparative context: